Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
DBV Technologies has filed its 2022 Annual Report on Form 10-K with the SEC and the 2022 Universal Registration Document with the AMF. These documents can be accessed via the company's website and respective regulatory authorities. DBV is focused on developing Viaskin™, an innovative technology for immunotherapy, particularly for food allergies. The company emphasizes its commitment to transforming care for food allergic patients through its unique epicutaneous immunotherapy method. Both reports are also available in printed form at the company’s headquarters.
DBV Technologies reported its 2022 financial results on March 2, 2023. The company had cash and cash equivalents of $209.2 million, a significant increase from $77.3 million in 2021, primarily driven by financing activities totaling $194.1 million and tax credit reimbursements of $26.1 million. Despite this, net loss decreased marginally from $97.8 million in 2021 to $96.3 million in 2022, translating to a net loss per share of $1.24. Operating expenses were reduced by 3%, amounting to $101.5 million. The EVOLVE study of the modified Viaskin Peanut patch showed positive caregiver feedback, supporting the patch's usability.
DBV Technologies, a clinical-stage biopharmaceutical company, will report its full year 2022 financial results and provide a business update on March 2, 2023. The company will host a conference call and live audio webcast at 5:00 p.m. ET, where participants can dial in using US: 1-866-777-2509 or International: 1-412-317-5413. The event will also be streamed on the company’s website, with a replay available afterward. DBV Technologies specializes in epicutaneous immunotherapy through its proprietary platform, Viaskin, aimed at transforming food allergy care.
DBV Technologies has announced its participation at the AAAAI 2023 Congress in San Antonio, TX, scheduled for February 24-27, where it will present two scientific posters from the Phase 3 EPITOPE study focusing on the efficacy and safety of epicutaneous immunotherapy with Viaskin Peanut in peanut-allergic children aged 1-3 years. One poster will compare data in children with and without concomitant food allergies, while the second will address those with and without atopic dermatitis. Additionally, DBV will sponsor the AAAAI Fellows-in-Training Program reception and host a booth in the exhibit hall.
DBV Technologies has announced its participation in the SBV Securities Global Biopharma Conference from February 13 to 16, 2023. The company's CEO, Daniel Tassé, will present on February 16 and will also engage in one-on-one investor meetings throughout the day. A live webcast of the presentation can be accessed via the company's website, and a replay will be available for 90 days post-event. DBV Technologies focuses on Viaskin™, an innovative platform for immunotherapy aiming to treat food allergies with ongoing trials for Viaskin Peanut. The company is headquartered in Montrouge, France, and its shares trade under the ticker DBVT on Nasdaq.
DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, revealing significant transaction activity and asset holdings as of December 31, 2022. The liquidity account contained 149,793 shares valued at €292,804. Since the contract's initiation on July 1, 2018, the account initially had 41,159 shares and €432,367.25. In the six-month period, 1,685 buy and 1,610 sales transactions occurred, totaling 597,406 shares worth €2,383,510 in purchases, and 553,900 shares valued at €2,245,465 in sales. DBV Technologies continues to focus on its Viaskin platform for food allergy treatments.
As of December 31, 2022, DBVT reported a total of 94,137,145 shares outstanding, indicating a stable share structure. The total number of voting rights associated is 94,137,145, with a net total of 93,966,891 voting rights after excluding shares without voting rights. This data aligns with regulatory requirements under the Autorité des Marchés Financiers and emphasizes the company’s transparency in reporting.
DBV Technologies announced the FDA has lifted the partial clinical hold on its VITESSE Phase 3 trial, evaluating the Viaskin Peanut patch in peanut-allergic children. Patient screening is expected to start in Q1 2023, with topline results anticipated in 1H 2025. The FDA requested modifications to the trial protocol to support a Biologics License Application, including changes in daily wear time and safety assessments. DBV stated it has sufficient cash to fund operations through VITESSE topline data.
DBVT has released its monthly information as of November 30, 2022, detailing the total number of voting rights and shares. The company reported a total of 94,137,145 shares, with 94,137,145 gross voting rights and 93,966,891 net voting rights after accounting for shares without voting rights. This update complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT) announced its participation in the 5th Annual Evercore ISI HealthCONx Conference from Nov. 29 to Dec. 1, 2022. CEO Daniel Tassé will engage in a Fireside Chat on Nov. 30 at 8 a.m. ET and hold one-on-one investor meetings. A live webcast of the session will be available on the company's website, with a replay accessible for 90 days post-event. DBV Technologies focuses on developing Viaskin™, a non-invasive immunotherapy technology, targeting food allergies, particularly through its ongoing clinical trials of Viaskin Peanut.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
